Gowthami Morey Arepally, MD

Professor of Medicine
Associate Professor of Pathology
Professor of Pathology
Campus mail Duke Box 3486, Durham, NC 27710
Phone (919) 668-3696
Email address arepa001@mc.duke.edu

Gowthami M. Arepally, M.D. is a Professor of Medicine in the Division of Hematology at Duke University Medical Center and the Medical Director of Therapeutic Apheresis at Duke.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and applications of therapeutic apheresis for immunologic disorders.    Dr. Arepally’s long-standing research program investigates immunoregulatory mechanisms in HIT.  Current laboratory efforts focus on the role of complement activation in the immune pathogenesis of HIT, investigations of protamine/heparin antibodies and development of murine models for studies of the HIT immune response.  Clinical projects include applications of therapeutic apheresis, including development of a multi-site network for investigations of thrombotic microangiopathy.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania, 1993 - 1997
  • Chief Medical Resident, Medicine, Emory University, 1992 - 1993
  • Medical Resident, Medicine, Emory University, 1989 - 1992
  • M.D., Vanderbilt University, 1989

Publications

Bauer, T. L., G. Arepally, B. A. Konkle, B. Mestichelli, S. S. Shapiro, D. B. Cines, M. Poncz, et al. “Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.” Circulation 95, no. 5 (March 4, 1997): 1242–46. https://doi.org/10.1161/01.cir.95.5.1242.

PMID
9054855
Full Text

Arepally, G., S. E. McKenzie, X. M. Jiang, M. Poncz, and D. B. Cines. “Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.” Blood 89, no. 2 (January 15, 1997): 370–75.

PMID
9002937
Scholars@Duke

Arepally, G., S. E. McKenzie, X. M. Jiang, M. Poncz, and D. B. Cines. “FcγRIIA H/R131 polymorphism, subclass-specific IgG anti- heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.” Blood 89, no. 2 (January 15, 1997): 370–75. https://doi.org/10.1182/blood.v89.2.370.

Full Text

Jiang, X. M., G. Arepally, M. Poncz, and S. E. McKenzie. “Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED).” J Immunol Methods 199, no. 1 (November 29, 1996): 55–59. https://doi.org/10.1016/s0022-1759(96)00164-0.

PMID
8960098
Full Text

Arepally, G., C. Reynolds, A. Tomaski, J. Amiral, A. Jawad, M. Poncz, and D. B. Cines. “Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia.” Am J Clin Pathol 104, no. 6 (December 1995): 648–54. https://doi.org/10.1093/ajcp/104.6.648.

PMID
8526207
Full Text

Arepally, G., A. Felcher, A. D. Moscioni, and A. A. Demetriou. “Proliferation of intraperitoneally transplanted microcarrier-attached rat liver cells.” Surgical Forum 39 (January 1, 1988): 396–97.

Scholars@Duke

Pages